Currently epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is widely used for treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.